Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Walter Liptak
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters).
- Questions
- 15on tracked calls
- Challenge rate
- 0%none of 15 questions
- Companies
- 2questioned at least once
- Reporting periods
- 7with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 15 of 15 questions from 2 companies
NDSNNordson Corporation14 questions · 7 reporting periods · 0 of 14 challenging
Calendar 2026 Q2
I wonder if there's a way you could quantify it for us a little bit more. Is it up single digits, double digits
Show response
Dan implied ATS backlog growth at or above the 18% overall without giving exact segment number. Naga clarified no structural lag between dispense and T&I, both seeing similar demand levels.
I think some of those 6 months cycle times from backlog to shipment is probably longer in industrial, but shorter in Medical and Advanced Tech
Show response
Dan and Naga explained it depends on mix, larger systems 3-6 months, consumables within the quarter. ATS lead times improved to 7-8 weeks from 16-18. Customer timing preferences often dictate delivery more than capacity.
Calendar 2026 Q1
is there any differences between prior kind of consumer electronics-led cycles versus this one?
Show response
CEO said order lead times are similar but cycle amplitude is dampened with smaller, more frequent orders. New advantages include manufacturing close to customers and improved on-time delivery in low 90s marching toward 95%.
is there a win rate? Like -- it sounds like you might be gaining market share here
Show response
CEO declined to share specific win rate data but confirmed four core growth drivers, innovation, delivery, quality, and geographic proximity, are enabling the team to leverage the full market opportunity.
Calendar 2025 Q4
as you look back, what do you think went best for you guys and what was the toughest?
Show response
CEO reflected on NBS Next progress: strategic discipline through segmentation is well-established, leadership-level performance approximately halfway to full potential. EBITDA margins expanded from 27% to 32%. Next phase focused on commercial excellence connecting segmentation, innovation, operations.
what inning are we at now, do you think with that, that operational EBITDA part of NBS Next?
Show response
CFO said margin accretion primarily comes from growth with normal incrementals, not standalone cost-cutting. CEO added 35% blended incremental means margins converge toward that number over time from current 32%, primarily through profitable growth.
Calendar 2025 Q3
Are you seeing your consumer products companies start to do redesign where they can make smart products that leverage the AI tech?
Show response
CEO said AI value creation is in very early stages across three vectors: improving Nordson product productivity for customers, new X-ray software subscription services using AI, and customer product redesign. All described as early-stage ideas.
I was wondering if you could talk a little bit about the quote-to-order cycle
Show response
CEO said 60-70% of IPS showing steady order entry but polymer processing and industrial coatings seeing customer pauses on large system orders, though customer pipelines remain robust. CFO added plastics pipeline is rebuilding from earlier in the year.
Calendar 2025 Q2
Do you still think you're going to be at the low end of the sales range for 2025?
Show response
CFO confirmed Q3 in line with full-year but said it's too early to call Q4 given pending trade policy deadlines in July/August, citing end market demand impact as biggest risk.
was that 5% growth in the second half on an organic basis or were you just talking about kind of growth in the future of 5%
Show response
CEO clarified 5% is through-cycle ATS growth expectation, with Q3 visibility definitely higher than 5% but no segment-level guidance provided.
Calendar 2025 Q1
so if I heard him right, you're thinking that MFS could be mid- to high end of the revenue guide, ATS at the low end and IPS at the low end?
Show response
CFO corrected interpretation and provided detailed segment-by-segment view for both low and high end of guidance range.
is it a new product? Is it Europe? Is it rest of world where you're seeing some green shoots?
Show response
Management provided extensive color: ARAG returning workforce from short-week program, new products in ICS and plastics, nonwovens and packaging doing well, parts mix strong.
Calendar 2024 Q4
at what point will we know that, you know, that there's not the recovery happening? Do you find it in the December quarter
Show response
CFO indicated Q1/Q2 results will provide better visibility on second-half trajectory, with current order patterns supporting near-term outlook.
where do you think ATS margins go? Or maybe another way to look at it, where do you think the operating leverage will be
Show response
CEO emphasized 27% EBITDA is best-in-class, but prioritized top-line growth over margin expansion, pointing to 14-15% R&D investment requirement.
IEXIDEX Corporation1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q3
are you cautious about 2026 or you're optimistic about the organic growth and especially given the platforms
Show response
Interim CFO guided 2026 consolidated incrementals at approximately 30%, with HST higher at 35-40%. CEO added degrees matter: incrementals spring much better at 3-4% organic growth versus flat.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| NDSN Nordson Corporation | 14 | 0%none of 14 questions |
| IEX IDEX Corporation | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 2 | 0%none of 2 questions | 1 |
| 2025 Q1 | 2 | 0%none of 2 questions | 1 |
| 2025 Q2 | 2 | 0%none of 2 questions | 1 |
| 2025 Q3 | 3 | 0%none of 3 questions | 2 |
| 2025 Q4 | 2 | 0%none of 2 questions | 1 |
| 2026 Q1 | 2 | 0%none of 2 questions | 1 |
| 2026 Q2 | 2 | 0%none of 2 questions | 1 |
- 2024 Q42 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q12 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q22 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2025 Q33 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2025 Q42 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2026 Q12 questions · challenge rate 0% (none of 2 questions) · 1 company
- 2026 Q22 questions · challenge rate 0% (none of 2 questions) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Demand6
- Innovation & R&D4
- Margin4
- Revenue Growth4
- Cloud & AI3
- Guidance Reliability3
- Trade Tariffs2
- Supply Chain1
- Competitive Dynamics1
- Product Launch1
Show all 11 topics
- Macroeconomic1